Drugs for Triglycerides Lowering

 

Drugs for Triglyceride Lowering: A Practical Clinical Guide

---

Introduction

Hypertriglyceridemia is a common lipid disorder associated with an increased risk of acute pancreatitis and, in selected populations, atherosclerotic cardiovascular disease (ASCVD). While lifestyle modification remains the cornerstone of therapy, pharmacological treatment is often required in patients with severe hypertriglyceridemia or persistent elevation despite non-pharmacological measures.

This article reviews the major drug classes used for triglyceride (TG) reduction and their clinical applications.

---

Understanding Triglyceride Levels

Triglyceride Level Classification

<150 mg/dL Normal

150–199 mg/dL Mild elevation

200–499 mg/dL Moderate elevation

≥500 mg/dL Severe hypertriglyceridemia

≥1000 mg/dL Very severe hypertriglyceridemia

The primary therapeutic goal in severe hypertriglyceridemia is prevention of acute pancreatitis.

---

1. Fibrates

Agents

Fenofibrate

Gemfibrozil

Mechanism of Action

Fibrates activate peroxisome proliferator-activated receptor-alpha (PPAR-α), leading to:

Increased lipoprotein lipase activity

Enhanced triglyceride clearance

Reduced hepatic VLDL production

Triglyceride Reduction

30–50%

Clinical Use

First-line drug therapy for severe hypertriglyceridemia (TG ≥500 mg/dL)

Prevention of pancreatitis

Important Adverse Effects

Myopathy

Elevated liver enzymes

Gallstones

Clinical Pearl

Fenofibrate is generally preferred over gemfibrozil when concomitant statin therapy is required because of a lower risk of myopathy.

---

2. Omega-3 Fatty Acids

Agents

Icosapent Ethyl

Omega-3-acid ethyl esters

Mechanism

Reduce hepatic VLDL synthesis

Increase triglyceride metabolism

Triglyceride Reduction

20–45%

Clinical Use

Severe hypertriglyceridemia

Adjunct to statins in selected high-risk patients

Key Evidence

Icosapent ethyl demonstrated significant cardiovascular risk reduction in high-risk patients with elevated triglycerides despite statin therapy.

Adverse Effects

Dyspepsia

Fishy aftertaste

Increased bleeding tendency

Increased incidence of atrial fibrillation in some studies

---

3. Statins

Common Agents

Atorvastatin

Rosuvastatin

Mechanism

Statins primarily reduce LDL cholesterol by inhibiting HMG-CoA reductase but also lower triglycerides.

Triglyceride Reduction

10–30%

Clinical Use

First-line therapy for ASCVD prevention

Patients with moderate hypertriglyceridemia and elevated cardiovascular risk

Clinical Pearl

Statins should be considered before triglyceride-specific therapy in most patients with mild-to-moderate hypertriglyceridemia and elevated ASCVD risk.

---

4. Niacin

Agent

Niacin

Mechanism

Reduces hepatic VLDL production

Lowers triglycerides and LDL cholesterol

Raises HDL cholesterol

Triglyceride Reduction

20–30%

Limitations

Modern guidelines rarely recommend niacin because randomized trials failed to demonstrate meaningful cardiovascular benefit.

Adverse Effects

Flushing

Hyperglycemia

Hepatotoxicity

Hyperuricemia

---

Emerging Therapies

Several novel agents are under investigation for severe hypertriglyceridemia:

ApoC-III inhibitors

ANGPTL3 inhibitors

RNA-based therapies targeting triglyceride metabolism

These drugs may become important options for familial chylomicronemia syndrome and refractory hypertriglyceridemia.

---

Guideline-Based Treatment Approach

Triglycerides 150–499 mg/dL

Lifestyle modification

Weight reduction

Improved glycemic control

Statin therapy when indicated

Triglycerides ≥500 mg/dL

Low-fat diet

Fibrate therapy

Prescription omega-3 fatty acids

Treat secondary causes

Triglycerides ≥1000 mg/dL

Very-low-fat diet

Fibrate plus omega-3 fatty acids

Strict diabetes control

Urgent prevention of pancreatitis

---

Secondary Causes to Exclude

Before initiating drug therapy, evaluate for:

Diabetes mellitus

Obesity

Hypothyroidism

Chronic kidney disease

Alcohol use

Pregnancy

Nephrotic syndrome

Medications (steroids, estrogens, thiazides, beta-blockers)

---

Key Takeaways

Fibrates are the most effective conventional drugs for triglyceride reduction.

Severe hypertriglyceridemia (≥500 mg/dL) requires treatment to prevent pancreatitis.

Statins remain the cornerstone of cardiovascular risk reduction.

Icosapent ethyl is the only omega-3 therapy with strong evidence for cardiovascular event reduction.

Lifestyle modification remains essential regardless of pharmacological therapy.